Pennsylvania-based Virpax Pharmaceuticals (VRPX) has priced its IPO of 1.8M common shares at $10.00/share, for gross proceeds of $18M.
The company was founded to create new formulations for the use of existing, approved drugs for various forms of pain management applications.
- Headquarters: West Chester, PA
- Founded: 2016
- virpaxpharma.com
Virpax's drug development pipeline
West Chester, PA-based preclinical stage biopharmaceutical company is focused developing non-opioid and non-addictive pain management products, using new drug delivery systems.
- It has rights to develop and sell a proprietary patented nonsteroid anti-inflammatory Topical Spray Film Delivery Technology for acute musculoskeletal pain (DSF100 or Epoladerm) and for chronic osteoarthritis of the knee (OSF200).
- The company also rights to injectable, long-acting local anesthetic Liposomal (Hydro) Gel Technology for postoperative pain management (LBL100 or Probudur).
- Virpax says that it also has plans on using our proprietary delivery technologies to develop anti-viral therapies as an anti-viral barrier to potentially prevent or reduce the risk or the intensity of viral infections in humans, including, influenza and SARS-CoV-2.
No comments:
Post a Comment